Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Mission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
2 investors
MOBILion Systems develops the MOBIE platform, a high-resolution ion mobility mass spectrometry (HRIM-MS) instrument that separates and identifies complex molecules in separation science. It serves pharmaceutical, biopharma, academic, and diagnostics labs across cell and gene therapy, therapeutic characterization, food and environmental testing, and biomarker research.
2 investors
Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms. The company has programs in infectious disease, oncology, and inflammation, with compounds in development including a broad-spectrum antiviral and a BRD4 inhibitor.
2 investors
Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
2 investors
Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another. It targets diseases with high unmet clinical need, initially in otology, ophthalmology, and diabetes.
2 investors
2 investors
Molecule operates a blockchain-based platform supporting decentralized science (DeSci), funding research projects and connecting scientists and entrepreneurs. It also features labs such as an autonomous AI agent for peptide drug discovery.
2 investors
Molecule.one applies machine learning to chemical synthesis, predicting synthetic routes and supporting chemistry research with an in-house synthetic and analytical laboratory. It serves pharmaceutical and life-science research through its computational and experimental chemistry platform.
2 investors
Moleculent develops biological discovery and disease understanding tools for scientists. The company focuses on decoding molecular foundations of biology to advance human health diagnostics and research.
2 investors
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
2 investors
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma. The biotech company is based near Leuven, Belgium.
2 investors
Moonlight Therapeutics is a clinical-stage biotech company developing an intradermal stamp-based immunotherapy for people with food allergies. Its lead therapy, MOON101, targets peanut allergy.
2 investors
Lighthouse Pharmaceuticals develops precision therapeutics for major unmet medical needs, with a lead program (LHP588), a gingipain inhibitor being tested in the Phase 2 SPRING trial for P. gingivalis-positive Alzheimer's disease. The company works in the biotechnology and drug development space, using patient responder analyses and dose modeling to advance its clinical candidates.
2 investors
MRM Health develops microbiome-based therapeutics using a precision-engineered platform called CORAL®, which designs and manufactures live bacterial consortia to treat diseases caused by microbiome dysbiosis. The company serves patients and pharmaceutical partners seeking novel disease-modifying treatments grounded in microbiome science.
2 investors
MycoMedica Life Sciences is a biopharmaceutical company developing psilocybin-based treatments for mental health and neurodegenerative disorders. It conducts non-clinical and human clinical studies of low-dose psilocybin, with an initial focus on Premenstrual Dysphoric Disorder and other neuropsychiatric conditions such as OCD, Opioid Use Disorder, and Parkinson's Disease.
2 investors
Mynvax develops engineered protein subunit vaccines using a protein stabilization platform, including influenza vaccine candidates based on stabilized hemagglutinin regions and thermo-tolerant vaccines against SARS-CoV-2 variants. Incubated at the Indian Institute of Science, the biotech startup collaborates with research labs, CDMOs, and vaccine manufacturers, with some programs funded by Indian government agencies.
2 investors
2 investors
2 investors
myTomorrows operates an online platform and patient navigation service that helps patients and their physicians discover and access clinical trials, expanded access programs, and treatments in development. It connects patients, treating physicians, and BioPharma research teams, supporting patient recruitment, expanded access management, and real-world data collection.
2 investors
NaDeNo develops nanoparticle drug delivery technology that encapsulates hard-to-deliver molecules through a proprietary one-step process without chemical modification. The platform serves pharmaceutical companies and biotech partners seeking to improve formulation of poorly soluble or hydrophobic therapeutics.
2 investors
Nagi Bioscience provides in vivo toxicity testing services using organism-on-chip technology with C. elegans models, serving pharmaceutical, chemical, and biotech companies seeking faster, ethical alternatives to traditional animal testing. The company delivers high-throughput developmental, reproductive, and eco-toxicity assays aligned with regulatory frameworks.
2 investors
Nanite develops resorbable polymer nanoparticles (PNPs) for virus-free genetic drug delivery, using high-throughput synthesis and AI to design precision delivery vectors for gene therapy. It targets subcutaneous gene therapy as an alternative to viral vectors and lipid nanoparticles.
2 investors
Nanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.
2 investors
Nanobots Therapeutics develops the MotionTx platform to create nanobots that penetrate tissues and enhance drug accumulation in target cells for therapeutic applications. The company is a spin-off of ICREA and IBEC resulting from research by Prof. Samuel Sánchez.
2 investors